Title
Radical versus partial nephrectomy, chronic kidney disease progression and mortality in US veterans.

Permalink
https://escholarship.org/uc/item/8q746764

Journal
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 33(1)

ISSN
0931-0509

Authors
Streja, Elani
Kalantar-Zadeh, Kamyar
Molnar, Miklos Z
et al.

Publication Date
2018

DOI
10.1093/ndt/gfw358

License
https://creativecommons.org/licenses/by/4.0/ 4.0

Peer reviewed
Radical versus partial nephrectomy, chronic kidney disease progression and mortality in US veterans

Elani Streja¹, Kamyar Kalantar-Zadeh¹², Miklos Z. Molnar³, Jaime Landman⁴, Onyebuchi A. Arah⁵ and Csaba P. Kovesdy³⁶

¹Harold Simmons Center for Kidney Disease Research and Epidemiology, Division of Nephrology and Hypertension, University of California Irvine Medical Center, Orange, CA, USA, ²Department of Medicine, UC Irvine School of Medicine, Irvine, CA, USA, ³Division of Nephrology, University of Tennessee Health Science Center, Memphis, TN, USA, ⁴Department of Urology, UC Irvine School of Medicine, Irvine, CA, USA, ⁵Department of Epidemiology, School of Public Health, University of California, Los Angeles, CA, USA and ⁶Nephrology Section, Memphis Veterans Affairs Medical Center, 1030 Jefferson Ave., Memphis, TN 38104, USA

Correspondence and offprint requests to: Csaba P. Kovesdy; E-mail: ckovesdy@uthsc.edu

ABSTRACT

Background. Partial nephrectomy is considered the preferred care for localized kidney tumors and may yield better patient and kidney survival and similar oncological outcomes compared with radical nephrectomy. We sought to reexamine these hypotheses in a large nationally representative cohort of US veterans who underwent radical or partial nephrectomy.

Methods. We identified 7073 US veterans who had a partial or radical nephrectomy between 2004 and 2013. We collected data on estimated glomerular filtration rate (eGFR) prior to admission for nephrectomy surgery, immediately after surgery and 180 days postsurgery. We evaluated the association of nephrectomy type and eGFR at different time points with long-term mortality risk in adjusted survival models.

Results. Patients who underwent radical (compared to partial) nephrectomy had a 2-fold greater decline in eGFR (−21.8 ± 17.7 versus −10.3 ± 17.4 mL/min/1.73 m²) immediately after surgery. This larger drop in eGFR resulted in a larger proportion of radical nephrectomy patients having an eGFR <60 mL/min/1.73 m² at ≥180 days postsurgery. Radical (compared to partial) nephrectomy patients also exhibited a 2.2-fold higher mortality [adjusted death hazard ratio 2.21 (95% confidence interval 1.91–2.55)]. Low eGFRs prior to surgery and 180 days postsurgery were associated with higher risk of postnephrectomy death.

Conclusions. Worse postnephrectomy kidney function and higher mortality were observed with radical nephrectomy, and a low presurgical eGFR and a greater decrease in eGFR postsurgery were associated with worse mortality irrespective of the type of nephrectomy. Additional studies are needed to examine predictors of postnephrectomy outcomes.

Keywords: chronic kidney disease, eGFR, partial and radical nephrectomy, renal cell carcinoma, survival analysis

INTRODUCTION

Renal cancer is one of the 10 most frequent cancers reported in the USA. The American Cancer Society estimates that there will be 64 000 new cases this year [1]. The treatment of choice for nonmetastatic renal cancer is nephrectomy. Radical nephrectomy (RN) was popularized by Robson et al. in 1969 [2]. Between 1990 and 2000, a different procedure referred to as partial nephrectomy (PN) [3, 4] was perfected, also referred to as ‘nephron-sparing surgery’ [5]. In 2009, the American Urological Association Guideline for Management of the Clinical T1 Renal Mass [6] recommended nephron-sparing approaches to be considered in all patients with a clinical T1 renal mass based on data demonstrating an increased risk of chronic kidney disease (CKD) associated with RN and a direct correlation between CKD and morbidity cardiovascular events and mortality. In the past 5 years there has been an increased trend in performing PN and authors have criticized the slow implementation of the guidelines [7].

The paradigm proposed by the guidelines implies that the difference in mortality between RN and PN will likely be accounted for by the increased cardiovascular risk conferred by a lower estimated glomerular filtration rate (eGFR) after surgery in RN patients. This is based on relatively short-term observational studies and supported by long-term data showing an increased risk of cardiovascular disease and death in kidney transplant donors [8]. In this study we explored this hypothesis in a large, nationally representative contemporary cohort of US veterans. We hypothesized that patients who received PN had
better patient and kidney survival than those who received RN, likely due to the preservation of nephron mass.

**MATERIALS AND METHODS**

**Cohort definition**

The institutional review committees at the Memphis and Long Beach Veterans Affairs Medical Centers approved the study. Our study utilized data from a cohort study examining risk factors in patients with incident CKD [Racial and Cardiovascular Risk Anomalies in CKD (RCAV) study] [9, 10]. From a cohort of 3 582 478 US veterans with a stable eGFR ≥60 mL/min/1.73 m² at baseline (1 October 2004 and 30 September 2006), we identified 7835 patients who had either a PN or RN between 1 October 2004 and 30 September 2012. We then removed patients who had more than one nephrectomy surgery \((n = 166)\), patients who had end-stage renal disease (ESRD) before the date of the nephrectomy \((n = 44)\) and patients with no serum creatinine measurement and therefore no eGFR before hospital admission for nephrectomy \((n = 286)\) or after the nephrectomy procedure \((n = 129)\). Our final cohort consisted of 7073 patients (Supplementary data, Figure S1).

Sociodemographic characteristics, comorbid conditions, blood pressure and laboratory characteristics were obtained as previously described [11, 12] but recorded at the time of surgery (or baseline). Information about age, sex and race were obtained from the VA Corporate Data Warehouse (CDW) and from Medicare through the VA–Medicare data merge project [13].

**Nephrectomy: intervention assessment**

Patients were identified as having a nephrectomy if they had a surgical procedure listed in the VA Inpatient Medical SAS Datasets [International Classification of Diseases, Ninth Revision (ICD-9) codes 5551 or 5552 (RN) or 554 (PN)]. Only patients who had a single procedure throughout follow-up were included (e.g. patients who had a PN followed by an RN were excluded).

The eGFR was calculated according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [14] using extracted serum creatinine measurements from the national Veterans Affairs (VA) Corporate Data Warehouse LabChem data files.

**Outcomes**

Data on all-cause mortality were obtained from the VA Vital Status Files (VSF), which contained dates of death or last medical or administrative encounter from all sources in the VA system, with 98.3% sensitivity and 99.8% specificity when compared with the National Death Index as the gold standard [15].

**Statistical analysis**

Descriptive analyses were performed and skewed variables (mean income) were log transformed. The start of the follow-up period was the date of nephrectomy surgery or the eGFR measurement date after surgery. Patients were followed until death or were censored at the date of the last health care or administrative visit, or on 26 July 2013.

Individual eGFR measurements and the differences between measurements prior to admission for surgery (presurgery), immediately after surgery, 180 days postnephrectomy (postsurgery) and last measurement after nephrectomy were collected and summarized. With the exception of measurements collected immediately after surgery, all measurements were taken from outpatient data only. The postsurgery date of 180 days was used because this is the time needed for renal function to stabilize according to prior literature [16]. Slopes of eGFR change per year were measured in patients who had at least three eGFR measurements 180 days postsurgery until the end of follow-up using mixed models. Multivariable linear regression models examining the effect of RN versus PN on postsurgery eGFR were performed.

In survival analyses, we examined the long-term mortality risk associations of RN (versus PN) and presurgery and postsurgery eGFR as continuous predictors and in groups \((\geq 75\) reference), \(60–<75\), \(45–<60\) and \(< 45\) mL/min/1.73 m²). Short-term mortality risk analyses (or death risks within the first 180 days postsurgery) were evaluated comparing RN versus PN. Associations were examined using Kaplan–Meier methods and unadjusted and adjusted Cox proportional hazard regression models. Associations of continuous eGFR with mortality were also modeled using restricted cubic splines.

Adjusted models included the following covariates based on *a priori* considerations: age, gender, race/ethnicity, marital status, service connectedness (a measure indicating whether one or more of a patient’s comorbidities were caused by their military service, resulting in certain privileges such as preferential access to care and lower copayments), per capita income, ever use of an angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) over the cohort follow-up time, body mass index (BMI), systolic and diastolic blood pressure, comorbidities (hypertension, diabetes, myocardial infarction, angina, cerebrovascular disease, congestive heart failure, peripheral artery disease, liver disease, peptic ulcer disease, rheumatic disease, malignancy, hemiplegia, HIV/AIDS and depression) and year of nephrectomy procedure.

Mediation analysis was conducted to assess possible mediation of the effect of RN versus PN on mortality by the change in eGFR postnephrectomy (eGFR 180 days postsurgery—presurgery eGFR) using recently published causal analytical methods [17]. In the sensitivity analysis, we additionally evaluated eGFR 180 days postnephrectomy as the mediator. For these analyses, associations of RN versus PN with mortality for each 1 mL/min/1.73 m² decrease in eGFR (or for each 10 mL/min/1.73 m² lower postsurgery eGFR in sensitivity analyses) were evaluated using logistic regression models. This mediation analysis additionally involved estimating and combining the regressions of eGFR change (mediator) on RN versus PN exposure and of mortality (outcome) on RN versus PN exposure and eGFR change to obtain the natural direct and indirect effects as well as the controlled direct effect of RN versus PN. The total effect of RN on mortality is commonly decomposed into the pure natural direct and total natural indirect effect. The pure natural direct effect of RN (versus PN) was defined as the effect of RN...
on mortality if (individual patients’) eGFR change attained the value it would have had under non-exposure to RN (i.e., under PN instead). The total natural indirect effect of RN on mortality captured how much the mortality outcomes would change on average under RN (versus PN) intervention through the continuous mediator of eGFR change. The controlled direct effect can be interpreted as the effect of RN (versus PN) on mortality had patients’ eGFR change 180 days postnephrectomy been fixed at a uniform level. The proportion of the total effect of RN on mortality mediated by eGFR change 180 days postnephrectomy was also estimated and reported.

We also performed sensitivity analyses by excluding patients whose indication for nephrectomy was other than confirmed renal cancer. Statistical analyses were performed using Stata MP Version 12 (StataCorp, College Station, TX, USA).

### RESULTS

#### Baseline characteristics

We selected 7073 patients, 4795 of whom underwent RN and 2278 of whom underwent PN between 1 October 2004 and 30 September 2012. The median observation time from the date of surgery to the end of follow-up was 45 [interquartile range (24–69)] months. Characteristics of RN versus PN patients at the time of nephrectomy are shown in Table 1. The two groups were similar in terms of comorbidities. RN patients were older and had lower prenephrectomy eGFR (P < 0.001 each).

#### Deterioration of kidney function after radical versus partial nephrectomy

Presurgery eGFRs were obtained at a median of 14 (IQR 7–25) days prior to the nephrectomy surgery date. The posturgery eGFRs were obtained within 1 week of surgery (99% of patients had an eGFR recorded the day after surgery). Posturgery eGFRs were obtained at a median of 226 (IQR 198–282) days or 7 (IQR 6–9) months after surgery, and the last measurement obtained after surgery was at a median 39 (IQR 21–60) months after surgery. Table 2 presents the mean eGFR for the total cohort and by nephrectomy type at each time point, and the course of eGFR changes by nephrectomy type are shown in Figure 1. As expected, eGFR decreased after nephrectomy, and the decline was 2-fold greater for RN versus PN, i.e. −21.8 ± 17.7 versus −10.3 ± 17.4 mL/min/1.73 m², respectively. After the initial eGFR decline postnephrectomy, the average eGFR remained relatively stable in both groups for the remainder of the observation period. As a consequence of the greater decrease in eGFR, patients who had an RN were more likely than PN patients to exhibit a postnephrectomy eGFR <60 mL/min/1.73 m² (Supplementary data, Figure S2). In multivariable adjusted linear regression analyses, RN compared with PN was associated with a 19 mL/min/1.73 m² lower (worse) postnephrectomy eGFR [$\beta = −19.51$ [95% confidence interval (CI) −20.44 to −18.59], $P < 0.001$] and a 18 mL/min/1.73 m² lower eGFR when further adjusted for presurgery eGFR [$\beta = −18.35$ (95% CI −19.01 to −17.59), $P < 0.001$].

| Table 1. Differences in baseline characteristics between RN and PN |
|---------------------|---------------------|
|                     | PN                  | RN                  |
| N                   | 2278                | 4795                |
| Age (years), mean ± SD | 62 ± 9              | 64 ± 10             |
| Gender (% female)   | 3.5                 | 3.7                 |
| Marital status (%)  |                     |                     |
| Married             | 51                  | 51                  |
| Single              | 11                  | 9                   |
| Divorced            | 33                  | 33                  |
| Widow               | 5                   | 7                   |
| Race (%)            |                     |                     |
| White               | 73                  | 79                  |
| African American    | 22                  | 16                  |
| Hispanic            | 3                   | 3                   |
| Other               | 2                   | 2                   |
| Presurgery eGFR (mL/min/1.73 m²), mean ± SD | 81 ± 19 | 77 ± 20 |
| Mean annual income ($) | 20 722 (11 540–31 685) | 20 807 (12 083–31 876) |
| Service connectedness (% yes) | 48 | 44 |
| Ever ACEI/ARB use (%) | 72 | 68 |
| Systolic BP (mmHg), mean ± SD | 135 ± 18 | 135 ± 19 |
| Diastolic BP (mmHg), mean ± SD | 77 ± 11 | 76 ± 12 |
| BMI (kg/m²), mean ± SD | 30.9 ± 6.1 | 29.2 ± 6.3 |
| Comorbidities (%) |                     |                     |
| Hypertension        | 82                  | 80                  |
| Diabetes            | 37                  | 35                  |
| Cardiovascular disease | 31                | 31                  |
| Myocardial infarction | 29             | 30                  |
| Angina              | 7                   | 6                   |
| Percutaneous coronary intervention | <1 | <1 |
| Coronary artery bypass graft | 1 | 1 |
| Congestive heart failure | 8 | 10 |
| Cerebrovascular disease | 9 | 9 |
| Peripheral arterial disease | 5 | 5 |
| Chronic lung disease | 33                 | 34                  |
| Depression          | 21                  | 14                  |
| Kidney cancer, n (%) | 2145 (94%)         | 4158 (87%)          |
| Charlson Comorbidity Index, median (IQR) | 3 (2–4) | 3 (2–4) |

| Table 2. eGFRs (mL/min/1.73 m²) recorded at time points throughout the observation period in PN and RN patients |
|---------------------|---------------------|---------------------|
| Time point | Total PN | Total RN |
| Presurgery | 78.5 ± 19.4 | 81.3 ± 18.9 | 77.2 ± 19.6 |
| Immediately after surgery | 60.4 ± 20.2 | 71.0 ± 22.2 | 55.3 ± 17.0 |
| At least 180 days postsurgery | 60.5 ± 20.3 | 74.8 ± 20.3 | 53.6 ± 16.7 |
| Last eGFR obtained postsurgery | 61.9 ± 21.8 | 73.8 ± 21.9 | 56.2 ± 19.3 |

Values are given as mean ± SD.

In 3666 RN and 1714 PN patients with at least three available eGFR values [median 12 (IQR 7–19) measurements] 180 days postsurgery, the average slope was positive for both groups, showing a continuous albeit slow process of recovery or compensation 180 days postsurgery throughout the observation time, with a relatively larger increase in the RN group (RN: +0.65 ± 2.29 versus PN: +0.04 ± 2.47 mL/min/1.73 m²/year; $P < 0.0001$).
In a Kaplan–Meier plot of survival from surgery to the end of follow-up, there was a survival advantage for PN, as shown in Figure 2. In adjusted Cox proportional hazard models, patients who underwent RN had a >2.2-fold increased risk of death compared with those who had a PN [HR 2.21 (95% CI 1.91–2.55)]. In examining short-term mortality risk, or risk of death within 180 days postsurgery, RN patients had a 2.8-fold higher death risk compared with those who had a PN in fully adjusted models [hazard ratio (HR) 2.82 (95% CI 1.89–4.19)]. A sensitivity analysis after restricting the data to only patients with confirmed renal cancer (eliminating nephrectomy for other indications, n = 770) showed similar results [HR 2.27 (95% CI 1.95–2.65)].

Impact of eGFR on mortality

Lower presurgery eGFR was associated with a higher mortality risk (Supplementary data, Figure S3) in both unadjusted and adjusted models where we evaluated the association of eGFR groups (<45, 45–<60, 60–<75, ≥75 mL/min/1.73 m²) with mortality and used the highest (best) eGFR group (≥75 mL/min/1.73 m²) as a reference. For presurgery, each 10 mL/min/1.73 m² lower eGFR prior to surgery was associated with a significantly higher mortality risk [HR 1.11 (95% CI 1.08–1.15)], with similar associations in PN [HR 1.09 (95% CI 1.01–1.18)] and RN [HR 1.11 (95% CI 1.07–1.14)] strata (P for interaction = 0.41).

Compared with patients with a postsurgery (obtained 180 days postnephrectomy) eGFR ≥75 mL/min/1.73 m², patients with a lower (worse) postsurgery eGFR had a significant trend toward higher mortality risk (P for trend <0.001; Figure 3 and Supplementary data, Figure S4), where patients with a postsurgery eGFR <45 mL/min/1.73 m² had a 35% higher risk of mortality in adjusted models [HR 1.35 (95% CI 1.10–1.65)]. However, in patients with presurgery eGFR ≥60 mL/min/1.73 m² (normal kidney function), this association was attenuated and there was no clear association between lower (worst) eGFR and mortality in adjusted models. Similarly, each 10 mL/min/1.73 m² decrease in postsurgery eGFR was also associated with a
shortly of patients with presurgery normal kidney function (eGFR ≥60 mL/min/1.73 m²).

The interaction between percent change and presurgery eGFR. The natural direct effect odds ratio (OR) of RN versus PN via mediation analyses, including adjustment for presurgery eGFR was associated with a 4% higher risk of mortality [HR 1.04 (95% CI 1.01–1.07), P = 0.007]. The interaction between percent change and presurgery eGFR was not significant for the mortality outcome (P = 0.20).

Mediation analyses

We analyzed if eGFR changes postsurgery (presurgery to 180 days postsurgery) could account for the increased mortality in RN versus PN via mediation analyses, including adjustment for presurgery eGFR. The natural direct effect odds ratio (OR) of RN versus PN and mortality was 2.83 (95% CI 2.29–3.50), while the natural indirect effect OR per 1 mL/min/1.73 m² decrease in eGFR on mortality was 0.88 (95% CI 0.79–0.99). The controlled direct effect OR was 2.94 (95% CI 2.31–3.75) and the mediated total effect OR was 2.49 (95% CI 2.09–2.98). These results demonstrate that the difference in the magnitude of the eGFR decrease postnephrectomy accounts for ~23% of the increased risk of mortality for RN versus PN. In the sensitivity analysis, where eGFR 180 days postsurgery was evaluated as the mediator, results were similar (see Supplementary data).

**DISCUSSION**

This study confirms that mortality is higher after RN than after PN and that eGFR is lower after RN. The data also showed that after a decrease in the nephron pool by PN or RN surgery, the eGFR stabilized or slightly improved in the majority of patients for the remainder of the observation period. The typical progressively declining trajectory of eGFR observed in patients with CKD from other (medical) causes was absent in the majority of nephrectomy patients and was no more frequent after RN, in spite of this procedure producing a more profound decrease in postsurgery eGFR.

Our data do not support the hypothesis that the increased mortality in RN patients as compared with PN patients is attributable to the eGFR changes induced by surgery (nephron sparing). The results of our mediation analysis indicate that eGFR 180 days postsurgery accounts for only 32% of the increased risk in mortality seen in RN versus PN patients.

The only randomized clinical trial for head-to-head comparison of RN and PN [18] concluded that both methods provide excellent oncologic results. Survival was better for PN patients in the intent-to-treat population, but this was not significant in the targeted population (those with clear cell carcinoma). The trial was stopped early because of poor enrollment and was criticized for having randomization problems [19, 20].

The current recommendations [6] are based on the ‘nephron-sparing’ concept. They are supported by retrospective studies showing lower survival for RN. The increased relative risk of mortality associated with RN versus PN ranges from 15–25% [21, 22] to 250% [23]. Two meta-analyses [24, 25] published simultaneously confirmed the improved survival for PN patients. Studies showing increased long-term risk in kidney transplant donors also support this concept [8].

There is little evidence that the better survival of PN patients is attributable to nephron sparing. In patients who have undergone a nephrectomy, reduced GFR was shown to be associated with decreased overall survival [26]. A small study showed an increased mortality in patients with low eGFR after PN [27], but the data were not adjusted for presurgery eGFR. An increased risk of cardiovascular events after RN was also reported [28, 29].

Studies comparing the course of GFR decline in patients with low GFR attributable to CKD or to nephrectomy showed a much more benign course for postnephrectomy patients [30, 31]. In a large study, the eGFR after RN showed a slow improvement over the first 5 years [32].

There are a few possible interpretations for the lack of association between eGFR and mortality in RN and PN. First, one could speculate that RN had a higher rate of cancer-related mortality. Multiple studies have shown, however, that the difference in mortality is attributable to noncancer overall survival [21, 22, 33, 34].

Second, one could speculate that the mortality is higher in patients undergoing RN, unrelated to GFR level, and perhaps the result of a bias by indication (higher-risk patients being triaged towards the RN procedure). A recent analysis by Schuch et al. [35] using sophisticated methodology showed that patients undergoing PN had improved overall survival compared with noncancer patients, suggesting that PN patients have a survival advantage over RN patients and a possible selection bias is responsible for improved overall survival in PN versus RN patients. However, in a follow-up study the authors showed that PN had a higher risk of morbidity when compared with noncancer patients [36].

There are only a few studies that examine the risk of nonfatal and fatal cardiovascular events after nephrectomy. In two

![FIGURE 3: Hazard ratio for mortality in groups for eGFR 180 days postnephrectomy (eGFR ≥75 mL/min/1.73 m² as reference) in unadjusted and adjusted models in the total cohort and in a subcohort of patients with presurgery normal kidney function (eGFR ≥60 mL/min/1.73 m²).](image-url)
studies, cardiovascular death in RN was more than twice that in PN [34, 37]. In another study, there were an increased number of cardiovascular events but no increase in the time to the first event or the risk of cardiovascular death [38]. In our opinion, it is difficult to determine with certainty the mechanisms for better survival in PN versus RN without an in depth analysis of the cause of death and preexisting comorbidities related to it.

The strengths of this study include use of the large VA database with detailed preprocedure comorbidity data and vital status at the end of the study available in all patients. The study is limited, however, by its retrospective observational aspect. The study was also limited in the duration of follow-up and it is conceivable that after a longer observation time, the reduced eGFR of RN patients could account for decreased survival. Another limitation is the small number of women included in the cohort. Information on important confounders such as tumor size, cancer stage and pathology type and on important outcome characteristics such as cause of death and date of oncological recurrence were not available. It is possible that more advanced renal cancer may have contributed to survival differences in RN versus PN. Lastly, the possibility of additional unidentified confounders or residual confounding could also limit the interpretation of our results.

CONCLUSIONS

We have shown that RN (versus PN) is associated with a higher risk of long-term mortality and a lower postnephrectomy eGFR. In this regard, this study supports the current guidelines of PN for management of nonmetastatic renal cancer. We have shown, however, that after a relatively short-term observation time, increased mortality cannot be accounted for by the difference in eGFR induced by the procedure (RN or PN). The cause of the difference in survival between RN and PN reported by most authors remains unknown. Further studies including large randomized clinical trials with additional oncological data are needed to examine pathophysiological mechanisms postnephrectomy and to determine the most optimal management strategy in renal cancer.

SUPPLEMENTARY DATA

Supplementary data are available online at http://ndt.oxfordjournals.org.

ACKNOWLEDGEMENTS

E.S. and C.P.K. had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. This study is supported by grant 1R01DK096920 from the National Institutes of Health to C.P.K. and K.K.-Z. and is the result of work supported with resources and the use of facilities at the Memphis VA Medical Center and the Long Beach VA Medical Center. Support for VA/Centers for Medicare and Medicaid Services data is provided by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, VA Information Resource Center (Project Numbers SDR 02-237 and 98-004). The VA and NIH did not participate in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. C.P.K. and K.K.-Z. are employees of the Department of Veterans affairs. Opinions expressed in this article are those of the authors’ and do not necessarily represent the opinion of the Department of Veterans Affairs.

CONFLICT OF INTEREST STATEMENT

K.K.-Z. has received honoraria and/or support from Abbott, AbbVie, Alexion, Amgen, American Society of Nephrology, AstraZeneca, AVEO, Chugai, DaVita, Fresenius, Genetech, Haymarket Media, Hospira, Kabi, Keryx, National Institutes of Health, National Kidney Foundation, Relypsa, Resverlogix, Sanofi, Shire, Vifor and ZS-Pharma. C.P.K. has received honoraria from Sanofi-Aventis, Relypsa and ZS Pharma. All other authors have no conflicts of interest or financial disclosures. The results of this article have not been published previously in whole or part, except for abstract submission to the 46th American Society of Nephrology Kidney Week, November 11–14, 2014, Philadelphia, PA, USA.

REFERENCES


Received: 26.7.2016; Editorial decision: 6.9.2016